A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component [0.03%]
吉西他滨联合阿昔替尼治疗主要向肉瘤样分化肾细胞癌的疗效和安全性：一项前瞻性II期临床试验
Inkeun Park,Hyo Jin Lee,Woo Kyoon Bae et al.
Inkeun Park et al.
Introduction We conducted a multicenter, phase 2 trial using gemcitabine plus axitinib (GX) in patients with recurrent or metastatic sarcomatoid renal cell carcinoma (SRCC) to evaluate its efficacy and safety. Methods Patients with advanced...
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC [0.03%]
阿帕替尼联合培美曲塞和卡铂治疗EGFR和ALK阴性未接受过治疗的非鳞状细胞IV期非小细胞肺癌患者的Ⅰ期减剂量研究
Meijuan Huang,Youling Gong,Jiang Zhu et al.
Meijuan Huang et al.
Objective Apatinib is an oral small molecule anti-angiogenic drug. This phase I study aimed to establish the feasible dose of apatinib in combination with pemetrexed plus carboplatin as first-line therapy for epidermal growth factor recepto...
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer [0.03%]
索坦治疗高危（卡介苗耐药）非肌层浸润性膀胱癌的Ⅱ期临床试验
Haris Zahoor,Maria C Mir,Pedro C Barata et al.
Haris Zahoor et al.
Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity against bladder cancer. We hypothesized that treatment with sunitinib may decrease progression or recurrence in non-muscle invasive...
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms [0.03%]
JAK/STAT信号传导途径和组蛋白去乙酰基酶的联合靶向作用：鲁索利替尼和伏立诺他针对骨髓增殖性肿瘤的协同效应
Xing Hao,Wen Xing,Jiajia Yuan et al.
Xing Hao et al.
The majority of patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) harbor a gain of function mutation V617F in Janus kinase (JAK) 2. Although JAK2 inhibitors such as ruxolitinib have been shown to be clinically efficaci...
Anticancer evaluation of a novel dithiocarbamate hybrid as the tubulin polymerization inhibitor [0.03%]
一种新型二硫代氨基甲酸盐杂环管蛋白聚合抑制剂的抗肿瘤评价
Jia Liu,Dongwei Xue,Xingwang Zhu et al.
Jia Liu et al.
Novel quinoline-dithiocarbamate hybrids were synthesized and designed by the molecular hybridization strategy. All these derivatives were evaluated for their antiproliferative activity against three selected cancer cell lines (MGC-803, HepG...
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation [0.03%]
恶性胸腔积液对EGFR突变型非小细胞肺癌患者奥希替尼治疗的影响分析
Takahisa Kawamura,Hirotsugu Kenmotsu,Haruki Kobayashi et al.
Takahisa Kawamura et al.
3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non-small-cell lung cancers (NSCLC) with EGFR mutations. However, the efficacy of osimertinib in NSCL...
The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid [0.03%]
p-糖蛋白调节剂依拉立达联合给药对拉帕替尼药代动力学及脑和脑脊液分布的影响
Agnieszka Karbownik,Katarzyna Sobańska,Włodzimierz Płotek et al.
Agnieszka Karbownik et al.
Background Lapatinib is a small-molecule tyrosine kinase inhibitor of human epidermal receptor 2 (HER2) and EGFR that has currently been approved for the treatment of HER2-positive advanced and metastatic breast cancer (BC). The ATP-binding...
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells [0.03%]
新型微管靶向抗癌剂CKT0353可克服癌细胞的紫杉醇耐药性
Jelena Dinić,Carla Ríos-Luci,Ieva Karpaviciene et al.
Jelena Dinić et al.
Microtubule targeting agents (MTAs) are extensively used in cancer treatment and many have achieved substantial clinical success. In recent years, targeting microtubules to inhibit cell division has become a widespread pharmaceutical approa...
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma [0.03%]
IGF-1R通路活化及NPM-ALK G1269A突变使淋巴瘤产生克唑替尼耐药性
Yanrong Li,Kai Wang,Na Song et al.
Yanrong Li et al.
ALK-positive anaplastic large cell lymphoma (ALCL) represents a subset of non-Hodgkin's lymphoma that is treated with crizotinib, a dual ALK/MET inhibitor. Despite the remarkable initial response, ALCLs eventually develop resistance to criz...
Novel thiosemicarbazones induce high toxicity in estrogen-receptor-positive breast cancer cells (MCF7) and exacerbate cisplatin effectiveness in triple-negative breast (MDA-MB231) and lung adenocarcinoma (A549) cells [0.03%]
新型异噻唑碳二亚胺可使雌激素受体阳性乳腺癌细胞毒性增高（MCF7），并能加重三阴性乳腺癌（MDA-MB-231）和肺腺癌（A549）细胞的顺铂功效
Estefany Ingrid Medina-Reyes,Marco Antonio Mancera-Rodríguez,Norma Laura Delgado-Buenrostro et al.
Estefany Ingrid Medina-Reyes et al.
Cis-diamminedichloroplatinum(II) (CDDP), known as cisplatin, has been extensively used against breast cancer, which is the most frequent cancer among women, and lung cancer, the leading cancer that causes death worldwide. Novel compounds su...